MedTrace Logo

Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops

NCT06969001 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-09-09

No results posted yet for this study

Summary

To assess the single-dose and multiple-dose pharmacokinetics (PK), safety and tolerability of SCAI-005 eyedrops(axitinib) in healthy volunteers

Conditions

  • Wet Age Related Macular Degeneration

Interventions

DRUG

SCAI-005 0.04% or placebo

axitinib 0.014mg or placebo

DRUG

SCAI-005 0.08% or placebo

axitinib 0.028mg or placebo

DRUG

SCAI-005 0.08% or placebo 2drops

axitinib 0.056mg or placebo

Sponsors & Collaborators

  • SCAI Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-29
Primary Completion
2025-09-04
Completion
2025-09-04

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06969001 on ClinicalTrials.gov